Trovagene Closes $3.8M Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene said after the close of the market Tuesday that it has raised gross proceeds of $3.8 million from a private placement of stock and warrants.

The San Diego-based molecular diagnostics developer placed 940,000 units at a purchase price of $4 per unit. Each consists of one share of unregistered common stock and one warrant to purchase one share of common stock. The warrants are exercisable for five years from the date of closing at an exercise price of $5.32 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.